General Pharmacology Practice Questions

Q: Which of the following is NOT an action of bradykinin?

Vasoconstriction. **Explanation:** Bradykinin is a potent endogenous nonapeptide and a key mediator of the kinin-kallikrein system. It acts primarily through B1 and B2 receptors to modulate vascular and inflammatory responses. **Why Vasoconstriction is the Correct Answer:** Bradykinin is one of the most potent endogenous **vasodilators**. It induces vasodilation by stimulating the release of nitric oxide (NO), prostacyclin ($PGI_2$), and endothelium-derived hyperpolarizing factor (EDHF) from vascular endothelial cells. Therefore, it causes a decrease in peripheral vascular resistance and blood pressure, rather than vasoconstriction. **Analysis of Incorrect Options:** * **Increased vascular permeability:** Bradykinin causes contraction of endothelial cells in post-capillary venules, leading to gap formation and leakage of plasma into the interstitium (edema). * **Chemoattractant:** Bradykinin acts as a chemical mediator that attracts leukocytes to the site of injury or inflammation, facilitating the immune response. * **Pain on injection:** Bradykinin is a potent algogenic substance. It directly stimulates nociceptors (sensory nerve endings) and sensitizes them to other stimuli, which is why its injection causes intense local pain. **High-Yield Clinical Pearls for NEET-PG:** * **ACE Inhibitors & Cough:** ACE (Angiotensin-Converting Enzyme) is responsible for the degradation of bradykinin. ACE inhibitors lead to bradykinin accumulation in the lungs, causing the classic side effect of a **dry cough** and, rarely, **angioedema**. * **Hereditary Angioedema:** This condition is caused by C1 esterase inhibitor deficiency, leading to overproduction of bradykinin, resulting in recurrent episodes of swelling. * **Triple Response of Lewis:** Bradykinin plays a role in the "flare" component of the triple response due to its vasodilatory properties.

Q: The maximum tolerated dose of a new drug is evaluated in which phase of clinical trials?

Phase 1. **Explanation:** The primary objective of **Phase 1 Clinical Trials** is to establish the safety and tolerability of a new drug. This is achieved by determining the **Maximum Tolerated Dose (MTD)**—the highest dose of a drug that can be administered without causing unacceptable side effects. * **Why Phase 1 is correct:** It is the first stage of testing in humans (usually 20–80 healthy volunteers, except for toxic drugs like anti-cancer agents). Researchers use a "dose-escalation" design to identify the MTD and the Dose-Limiting Toxicity (DLT). It also evaluates the drug's pharmacokinetics (ADME) and pharmacodynamics. **Analysis of Incorrect Options:** * **Phase 2:** Focuses on **Efficacy** ("Does it work?") and finding the optimal therapeutic dose range in a small group of patients (100–300) with the target disease. * **Phase 3:** Focuses on **Confirmation** of efficacy and safety in a large patient population (1,000–3,000). It compares the new drug against the current "Gold Standard" (Standard of Care) or a placebo. * **Phase 4:** Also known as **Post-Marketing Surveillance**. It occurs after the drug is approved to detect rare or long-term adverse effects in the general population. **High-Yield Clinical Pearls for NEET-PG:** * **Phase 0:** Also called **Microdosing** studies; used to determine human PK parameters using sub-therapeutic doses. * **Phase 1:** Safety, Tolerability, MTD, and PK. * **Phase 2:** Therapeutic Exploration and Efficacy. * **Phase 3:** Therapeutic Confirmation and Comparative studies. * **Phase 4:** Post-marketing surveillance; identifies **Rare Adverse Effects** (e.g., Phocomelia with Thalidomide).

Q: What phase of clinical trials involves randomized controlled multicenter trials for a drug?

Phase 3. **Explanation:** **Phase 3** clinical trials are designed to confirm the efficacy and safety of a new drug in a large, diverse patient population (typically 1,000–3,000 patients). These are **Randomized Controlled Multicenter Trials (RCTs)** that compare the new drug against the current "Gold Standard" treatment or a placebo. This phase is critical for establishing the risk-benefit ratio and providing the definitive data required for New Drug Application (NDA) submission and marketing approval. **Why other options are incorrect:** * **Phase 1:** Focuses on **safety and tolerability** in a small group (20–80) of healthy volunteers (except for toxic drugs like anti-cancer agents). It is not multicenter or focused on efficacy. * **Phase 2:** Known as the **"Proof of Concept"** phase. It involves a smaller group of patients (100–300) to determine the therapeutic dose range and initial efficacy. While it can be randomized, it is rarely a large-scale multicenter trial. * **Phase 4:** This is **Post-Marketing Surveillance**. It occurs after the drug is launched to detect rare long-term adverse effects (e.g., Phocomelia with Thalidomide) and is not a controlled trial. **High-Yield Clinical Pearls for NEET-PG:** * **Phase 0:** Human Microdosing studies (sub-therapeutic doses) used to study pharmacokinetics. * **Phase 1:** Maximum Tolerated Dose (MTD) is determined here. * **Phase 2:** Highest rate of drug failure occurs in this phase. * **Phase 3:** Often referred to as "Pivotal Trials." * **Phase 4:** Helps in identifying "Low-frequency" adverse drug reactions (ADRs).

Q: Basiliximab is a monoclonal antibody against which receptor?

IL-2 receptor. **Explanation:** **Basiliximab** is a chimeric monoclonal antibody (mouse-human) that acts as a potent immunosuppressant. Its mechanism of action involves binding specifically to the **α-subunit (CD25)** of the **Interleukin-2 (IL-2) receptor** expressed on the surface of activated T-lymphocytes. By competitively inhibiting IL-2 from binding to its receptor, it prevents T-cell proliferation and activation, which are critical steps in the immune response against transplanted organs. **Analysis of Options:** * **Option A (IL-2 receptor):** Correct. Basiliximab (and Daclizumab) are IL-2 receptor antagonists used primarily as "induction therapy" in renal transplantation to prevent acute organ rejection. * **Option B (CD20):** Incorrect. **Rituximab** is the monoclonal antibody directed against CD20, primarily used in B-cell non-Hodgkin lymphomas and Rheumatoid Arthritis. * **Option C (INF-α):** Incorrect. While there are no major monoclonal antibodies targeting INF-α used in standard transplant protocols, drugs like Sifalimumab have been studied for SLE. * **Option D (IL-6):** Incorrect. **Tocilizumab** and Sarilumab are the monoclonal antibodies that target IL-6 receptors, used in Rheumatoid Arthritis and Cytokine Release Syndrome (CRS). **High-Yield Clinical Pearls for NEET-PG:** * **Indication:** Prophylaxis of acute organ rejection in renal transplants (Induction therapy). * **Mnemonic:** "Basiliximab binds the **B**-chain (actually the alpha chain/CD25) to block the **B**-last (T-cell blast/proliferation)." * **Side Effects:** Generally well-tolerated; unlike older agents, it does not typically cause cytokine release syndrome. * **Comparison:** Unlike Muromonab-CD3 (which depletes T-cells), Basiliximab only inhibits *activated* T-cells.

Q: Which of the following statements about phase IV clinical trials is true?

It is post-marketing surveillance of drugs. **Explanation:** **Phase IV Clinical Trials** are also known as **Post-Marketing Surveillance (PMS)**. These trials begin after a drug has been approved by regulatory authorities (like the FDA or CDSCO) and is available on the market for the general population. 1. **Why Option C is Correct:** Unlike Phase I-III trials, which involve a limited number of selected participants under controlled conditions, Phase IV monitors the drug's performance in the "real world." Its primary goal is to detect **rare adverse effects**, long-term risks, and benefits that were not evident during the shorter, smaller pre-approval trials. 2. **Why Other Options are Incorrect:** * **Option A:** Drugs for pediatric use undergo specific pediatric clinical trials (often Phase IIIb), but Phase IV is not defined by the age group; it is defined by the timing (post-approval). * **Option B:** Drugs for rare diseases are called **Orphan Drugs**. While they undergo Phase IV like any other drug, Phase IV itself is not a study specifically "for rare drugs." * **Option C:** "Human pharmacology and safety studies" refers to **Phase I** clinical trials, where the drug is first tested in a small group of healthy volunteers to determine safety and pharmacokinetics. **High-Yield Clinical Pearls for NEET-PG:** * **Phase 0:** Microdosing studies (sub-therapeutic doses) used to determine PK parameters. * **Phase I:** Safety and Tolerability (Healthy volunteers, except for oncology drugs). * **Phase II:** Therapeutic **Exploration** (Small group of patients; determines dose-range). * **Phase III:** Therapeutic **Confirmation** (Large multicentric RCTs; establishes efficacy against placebo or gold standard). * **Phase IV:** Post-marketing surveillance; identifies **idiosyncratic reactions** and rare side effects (e.g., the withdrawal of Rofecoxib due to cardiovascular risks).

Q: What is a specific side effect of thalidomide?

Phocomelia. **Explanation:** **Thalidomide** is a classic example of a potent **teratogen**. The correct answer is **Phocomelia**, a condition characterized by "seal-like limbs" where the long bones of the extremities are absent or significantly underdeveloped, causing the hands or feet to be attached directly to the trunk. 1. **Mechanism of Phocomelia:** Thalidomide was originally used in the 1950s as a sedative and anti-emetic for morning sickness. It was later discovered that exposure during the first trimester (specifically days 24–36 of gestation) inhibits angiogenesis and interferes with the protein **Cereblon**, which is essential for limb bud development. This led to the "Thalidomide Tragedy," resulting in thousands of babies born with phocomelia. 2. **Analysis of Incorrect Options:** * **Lymphopenia/Lymphocytosis:** Thalidomide has immunomodulatory effects (inhibits TNF-α), but it is not specifically known for causing significant fluctuations in lymphocyte counts as a primary diagnostic side effect. * **Optic Neuritis:** This is a classic side effect of **Ethambutol** (anti-tubercular drug), not thalidomide. Thalidomide is more commonly associated with peripheral neuropathy. **High-Yield Clinical Pearls for NEET-PG:** * **Current Uses:** Despite its teratogenicity, thalidomide is now a first-line treatment for **Multiple Myeloma** and **Erythema Nodosum Leprosum (ENL)**. * **Mechanism:** It acts by inhibiting **TNF-α** and angiogenesis. * **Regulatory Fact:** The thalidomide disaster led to the strengthening of the FDA and more stringent drug testing regulations (Kefauver-Harris Amendment). * **Contraception:** Due to its high teratogenic risk, it is strictly contraindicated in pregnancy (Category X) and requires the "STEPS" program for risk management.

Q: Which of the following is NOT a side effect of prostaglandins?

Convulsion. **Explanation:** Prostaglandins (PGs) are lipid compounds derived from arachidonic acid that act as local mediators. Their side-effect profile is directly linked to their physiological actions on smooth muscle and the central nervous system. **Why "Convulsion" is the Correct Answer:** Prostaglandins, particularly PGE2 and PGF2α, do not typically cause convulsions. In fact, some prostaglandins (like PGE1) have been studied for potential neuroprotective or anticonvulsant properties in specific contexts. Convulsions are not a recognized or common adverse effect of therapeutic prostaglandin analogues (like Misoprostol, Dinoprostone, or Carboprost). **Analysis of Incorrect Options:** * **Vomiting & Diarrhea:** These are the most common side effects of prostaglandins. PGs (especially PGF2α and PGE2) increase gastrointestinal motility and stimulate smooth muscle contraction in the gut, leading to nausea, vomiting, and watery diarrhea. * **Fever:** PGE2 acts on the thermoregulatory center in the anterior hypothalamus to increase the body’s "set-point," leading to pyrexia. This is why fever is a frequent side effect during the clinical use of prostaglandins for labor induction or abortion. **NEET-PG High-Yield Pearls:** 1. **Drug of Choice (DOC):** Misoprostol (PGE1) is the DOC for preventing NSAID-induced peptic ulcers. 2. **Obstetrics:** Carboprost (PGF2α) is used in Postpartum Hemorrhage (PPH) but is contraindicated in asthmatics due to bronchoconstriction. 3. **Ophthalmology:** Latanoprost (PGF2α) is used in glaucoma; its unique side effect is increased pigmentation of the iris and eyelashes. 4. **Cardiology:** Alprostadil (PGE1) is used to keep the Ductus Arteriosus patent in cyanotic heart diseases.

Q: Therapeutic monitoring of plasma drug levels is indicated for all of the following drugs except:

Warfarin. **Explanation:** Therapeutic Drug Monitoring (TDM) is indicated for drugs with a **narrow therapeutic index**, where the plasma concentration correlates well with the clinical effect or toxicity, and where the pharmacological effect is difficult to measure directly. **Why Warfarin is the correct answer:** While Warfarin has a narrow therapeutic index, we do **not** monitor its plasma levels. Instead, we monitor its pharmacodynamic effect using the **Prothrombin Time (PT)** and **International Normalized Ratio (INR)**. TDM is unnecessary when a simple, reliable physiological marker (like INR) can directly reflect the drug's efficacy and risk of toxicity. **Analysis of incorrect options:** * **Gentamicin:** An aminoglycoside with significant nephrotoxicity and ototoxicity. TDM is essential to ensure efficacy while minimizing toxicity, especially monitoring "trough" levels. * **Cyclosporine:** An immunosuppressant with highly variable pharmacokinetics and a narrow window. Monitoring is mandatory to prevent graft rejection (if levels are low) and nephrotoxicity (if levels are high). * **Phenytoin:** Follows **zero-order (non-linear) kinetics** at therapeutic doses. Small dose increases can lead to disproportionately large increases in plasma concentration, making TDM vital to avoid neurotoxicity. **High-Yield Clinical Pearls for NEET-PG:** * **TDM is NOT required for:** Drugs with a wide therapeutic index (e.g., Penicillin), drugs whose effect is easily measured (e.g., Antihypertensives via BP, Warfarin via INR, Hypoglycemics via Blood Glucose), and "hit-and-run" drugs (e.g., Omeprazole). * **Common TDM Drugs:** Lithium, Digoxin, Theophylline, Vancomycin, Tricyclic Antidepressants (TCAs), and Antiepileptics (Phenytoin, Carbamazepine).

Question 1

Which of the following is NOT an action of bradykinin?

Accepted Answer

Vasoconstriction

Answer

Increased vascular permeability

Answer

Chemoattractant

Answer

Pain on injection

Question 2

The maximum tolerated dose of a new drug is evaluated in which phase of clinical trials?

Accepted Answer

Phase 1

Answer

Phase 2

Answer

Phase 3

Answer

Phase 4

Question 3

What phase of clinical trials involves randomized controlled multicenter trials for a drug?

Accepted Answer

Phase 3

Answer

Phase I

Answer

Phase 2

Answer

Phase 4

Question 4

Therapeutic Drug Monitoring (TDM) involves measurement of plasma concentrations of drugs to determine if the drug levels are within the therapeutic range. For TDM to be clinically useful, which of the following criteria should be fulfilled?

Accepted Answer

When the clinical response cannot be easily monitored.

Answer

There should be a good relationship between plasma concentration and drug dosage.

Answer

The relationship between plasma drug concentration and therapeutic response and/or toxicity should be poor.

Answer

When pharmacodynamic tolerance is suspected.

Question 5

Basiliximab is a monoclonal antibody against which receptor?

Accepted Answer

IL-2 receptor

Answer

CD20

Answer

INF-α

Answer

IL-6

Question 6

Which of the following statements about phase IV clinical trials is true?

Accepted Answer

It is post-marketing surveillance of drugs

Answer

It is conducted for pediatric drugs

Answer

It is conducted for rare drugs

Answer

It is also called human pharmacology and safety studies

Question 7

What is a specific side effect of thalidomide?

Accepted Answer

Phocomelia

Answer

Lymphopenia

Answer

Lymphocytosis

Answer

Optic neuritis

Question 8

Which of the following is NOT a side effect of prostaglandins?

Accepted Answer

Convulsion

Answer

Vomiting

Answer

Fever

Answer

Diarrhea

Question 9

Therapeutic monitoring of plasma drug levels is indicated for all of the following drugs except:

Accepted Answer

Warfarin

Answer

Gentamicin

Answer

Cyclosporine

Answer

Phenytoin

Question 10

Therapeutic drug monitoring is particularly useful for which of the following drugs?

Accepted Answer

All the above

Answer

Lithium

Answer

Aminoglycoside antibiotics

Answer

Anticonvulsants

General Pharmacology — MCQs

General Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?